Le Lézard
Classified in: Health, Business
Subject: LIC

ORCA Dental AI and Planmeca Oy Partner for New Technology


HERZLIYA, Israel, Jan. 9, 2019 /PRNewswire-PRWeb/ -- Following the success of ORCA's solution for AI-driven cephalometric analysis, the company expanded its scope to additional dental fields and is focusing on building three AI engines for orthodontics, implants and diagnostics.

As part of this new partnership, ORCA's first solution automates the important process of teeth segmentation in CBCT scans. By automatically segmenting teeth and bone in seconds, ORCA provides information about every tooth, root inclination, impacted tooth position and supernumerary. Automating the process saves more than an hour per case and enables an array of new applications.

The second solution automates dental structure identification, instantly providing identification of the mandibular panoramic curve, the maxilla curve and tracing of the nerve canal.

"Root inclination diagnosis during orthodontic treatment is just one of the many applications our technology enables, as clear aligners grow in popularity to cover more complex cases," says Daniel Abraham, ORCA's founder and president. "Our technology bridges the knowledge and experience gaps and enables labs and practitioners to use real root information. There are many more use cases in orthodontics and prosthodontics. We are certain that Planmeca's decision to lead the market by once again embedding our technology in its software will enable its customers to enjoy new tools and unmatched efficiency."

"Planmeca's extensive tradition of introducing new technologies makes AI-powered tools a logical next step for us, as they have great potential to transform the way in which digital dentistry is performed on a day-to-day basis," states Helianna Puhlin-Nurminen, Planmeca Vice President of Digital Imaging and Applications. "ORCA Dental AI has convinced us of their ability to be an important partner in this process and we are looking forward to integrating new automated tools into our Planmeca Romexis software platform. This will provide users of our products with valuable and immediate information on each digital orthodontic, surgical and implant planning case ? making treatments more efficient, accurate and clinically feasible."

About ORCA Dental AI

ORCA Dental AI is the leading provider of artificial intelligence and machine-learning solutions for the dental industry, generating an array of immediate and accurate reports including teeth segmentation, dental structure identification, 2D and 3D image analyses and treatment suggestions.

ORCA combines its clinical expertise with deep learning and AI technologies in order to provide ground-breaking solutions in dentistry. ORCA's cognitive dental engine processes and analyzes 2D X-rays and CBCTs for the entire dental ecosystem, from general dentistry to specialties such as orthodontics and prosthodontics. For additional information, please visit http://www.orca-ai.com.

About Planmeca Oy

Planmeca Oy is a global leader in many fields of healthcare technology, with products distributed in over 120 countries worldwide. Planmeca's product range covers digital dental units, world-class 2D and 3D imaging devices and comprehensive CAD/CAM and software solutions. Headquartered in Helsinki, Finland, Planmeca is the largest privately held company in the field of dental equipment and the parent company of Planmeca Group. For more on Planmeca, visit http://www.planmeca.com.

 

SOURCE ORCA Dental AI


These press releases may also interest you

at 17:45
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

at 17:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...

at 16:30
Viatris Inc.  will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the...

at 16:30
WELL Health Clinic Network Inc. ("WELL"), a subsidiary of WELL Health Technologies Corp. , a digital healthcare company focused on...



News published on and distributed by: